OpenNashEarnings

Consumer Brands · NYSE: CL

Colgate-Palmolive earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 29 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Colgate is racing to rebuild its U.S. business around premium innovation and AI-driven marketing while emerging markets and Hill's pet nutrition carry global growth.

Growth was broad-based: organic sales rose in all four categories and four of five divisions. Emerging markets led, with India, Brazil and China cited as drivers. Hill's pet nutrition had a strong quarter, helped by therapeutic diets, cat and wet food, and the late-June launch of single-protein fresh diets. Toothpaste, toothbrush and mouthwash shares rose in several markets. North America remained the weak spot.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$5.4B+4.6% y/yQ3 2026
Q4 2024: $4.9B (worked out from the annual figure)Q4 ’24$4.9BQ1 2025: $4.9BQ1 ’25$4.9BQ2 2025: $5.1BQ2 ’25$5.1BQ3 2025: $5.1BQ3 ’25$5.1BQ4 2025: $5.2B (worked out from the annual figure)Q4 ’25$5.2BQ1 2026: $5.3BQ1 ’26$5.3BQ2 2026: $5.4BQ2 ’26$5.4BQ3 2026: $5.4BQ3 ’26$5.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$4.9B *
Q1 2025$4.9B
Q2 2025$5.1B
Q3 2025$5.1B
Q4 2025$5.2B *
Q1 2026$5.3B
Q2 2026$5.4B
Q3 2026$5.4B
Diluted EPS (GAAP)$0.94+3.3% y/yQ3 2026
Q1 2025: $0.85Q1 ’25$0.85Q2 2025: $0.91Q2 ’25$0.91Q3 2025: $0.91Q3 ’25$0.91Q1 2026: $0.80Q1 ’26$0.80Q2 2026: $0.86Q2 ’26$0.86Q3 2026: $0.94Q3 ’26$0.94
Data
Q1 2025$0.85
Q2 2025$0.91
Q3 2025$0.91
Q1 2026$0.80
Q2 2026$0.86
Q3 2026$0.94

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin20.3%−0.3 pts y/yQ3 2026
Q4 2024: 21.5%Q4 ’2421.5%Q1 2025: 21.9%Q1 ’2521.9%Q2 2025: 21.1%Q2 ’2521.1%Q3 2025: 20.6%Q3 ’2520.6%Q4 2025: 1.8%Q4 ’251.8%Q1 2026: 18.1%Q1 ’2618.1%Q2 2026: 19.0%Q2 ’2619.0%Q3 2026: 20.3%Q3 ’2620.3%
Data
Q4 202421.5%
Q1 202521.9%
Q2 202521.1%
Q3 202520.6%
Q4 20251.8%
Q1 202618.1%
Q2 202619.0%
Q3 202620.3%
Free cash flow$1.0B−6.2% y/yQ3 2026
Q4 2024: $1.1BQ4 ’24$1.1BQ1 2025: $476.0MQ1 ’25$476.0MQ2 2025: $776.0MQ2 ’25$776.0MQ3 2025: $1.1BQ3 ’25$1.1BQ4 2025: $1.3BQ4 ’25$1.3BQ1 2026: $609.0MQ1 ’26$609.0MQ2 2026: $867.0MQ2 ’26$867.0MQ3 2026: $1.0BQ3 ’26$1.0B
Data
Q4 2024$1.1B
Q1 2025$476.0M
Q2 2025$776.0M
Q3 2025$1.1B
Q4 2025$1.3B
Q1 2026$609.0M
Q2 2026$867.0M
Q3 2026$1.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$4.9Bd$4.9B$5.1B$5.1B$5.2Bd$5.3B$5.4B$5.4B
Gross margin60.3%60.8%60.1%59.4%60.2%60.6%61.5%60.2%
Operating income$1.1Bd$1.1B$1.1B$1.1B$92.0Md$964.0M$1.0B$1.1B
Operating margin21.5%21.9%21.1%20.6%1.8%18.1%19.0%20.3%
Net income$739.0Md$690.0M$743.0M$735.0M-$37.0Md$646.0M$693.0M$751.0M
Diluted EPS—$0.85$0.91$0.91—$0.80$0.86$0.94
Operating cash flow$1.3Bd$600.0M$884.0Md$1.3Bd$1.5Bd$747.0M$995.0Md$1.2Bd
Capital expenditure$184.0Md$124.0M$108.0Md$155.0Md$177.0Md$138.0M$128.0Md$134.0Md
Free cash flow$1.1B$476.0M$776.0M$1.1B$1.3B$609.0M$867.0M$1.0B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings